The Indianapolis Star

INDIGO Biosciences Launches CHRM1 (Cholinergic Receptor, Muscarinic 1) Reporter Assays for Cognitive Drug Discovery

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE COLLEGE, PA, UNITED STATES, March 19, 2026 ...
Nasdaq

Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 ...
BioWorld

Preclinical efficacy of M1/M4 receptor agonist in schizophrenia, cognitive impairment models

Researchers from Maplight Therapeutics Inc. presented preclinical data for the investigational muscarinic M1/M4 receptor agonist ML-007, being evaluated for the treatment of neuropsychiatric disorders ...

INDIGO Biosciences Launches CHRM1 (Cholinergic Receptor, Muscarinic 1) Reporter Assays for Cognitive Drug Discovery

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...